Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

Omid Hamid; Caroline Robert; Antoni Ribas; F. Stephen Hodi; Euan Walpole; Adil Daud; Ana S. Arance; Ewan Brown; Christoph Hoeller; Laurent Mortier; Jacob Schachter; Jianmin Long; Scot Ebbinghaus; Nageatte Ibrahim; Marcus Butler

doi:10.1038/s41416-018-0207-6

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

Omid Hamid^*, Caroline Robert, Antoni Ribas, F. Stephen Hodi, Euan Walpole, Adil Daud, Ana S. Arance, Ewan Brown, Christoph Hoeller, Laurent Mortier, Jacob Schachter, Jianmin Long, Scot Ebbinghaus, Nageatte Ibrahim, Marcus Butler

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

131 Scopus citations

Abstract

Background: Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT01866319). Methods: Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) or 10 mg/kg Q2W or Q3W. Response was assessed by independent central review per RECIST v1.1. Results: 1567 patients were treated and 84 (5%) had mucosal melanoma. Fifty-one of 84 were ipilimumab-naive. In patients with mucosal melanoma, the objective response rate (ORR) was 19% (95% CI 11–29%), with median duration of response (DOR) of 27.6 months (range 1.1 + to 27.6). Median progression-free survival (PFS) was 2.8 months (95% CI 2.7–2.8), with median overall survival (OS) of 11.3 months (7.7–16.6). ORR was 22% (95% CI 11–35%) and 15% (95% CI 5–32%) in ipilimumab-naive and ipilimumab-treated patients. Conclusion: Pembrolizumab provides durable antitumour activity in patients with advanced mucosal melanoma regardless of prior ipilimumab.

Original language	English
Pages (from-to)	670-674
Number of pages	5
Journal	British Journal of Cancer
Volume	119
Issue number	6
DOIs	https://doi.org/10.1038/s41416-018-0207-6
State	Published - 11 Sep 2018
Externally published	Yes

Funding

Funders	Funder number
Merck Serono
Roche
Meso Scale Diagnostics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41416-018-0207-6

Cite this

Hamid, O., Robert, C., Ribas, A., Hodi, F. S., Walpole, E., Daud, A., Arance, A. S., Brown, E., Hoeller, C., Mortier, L., Schachter, J., Long, J., Ebbinghaus, S., Ibrahim, N., & Butler, M. (2018). Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. British Journal of Cancer, 119(6), 670-674. https://doi.org/10.1038/s41416-018-0207-6

@article{65eec8a1c2714ddf9e66012e52c6b6fb,

title = "Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006",

abstract = "Background: Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT01866319). Methods: Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) or 10 mg/kg Q2W or Q3W. Response was assessed by independent central review per RECIST v1.1. Results: 1567 patients were treated and 84 (5%) had mucosal melanoma. Fifty-one of 84 were ipilimumab-naive. In patients with mucosal melanoma, the objective response rate (ORR) was 19% (95% CI 11–29%), with median duration of response (DOR) of 27.6 months (range 1.1 + to 27.6). Median progression-free survival (PFS) was 2.8 months (95% CI 2.7–2.8), with median overall survival (OS) of 11.3 months (7.7–16.6). ORR was 22% (95% CI 11–35%) and 15% (95% CI 5–32%) in ipilimumab-naive and ipilimumab-treated patients. Conclusion: Pembrolizumab provides durable antitumour activity in patients with advanced mucosal melanoma regardless of prior ipilimumab.",

author = "Omid Hamid and Caroline Robert and Antoni Ribas and Hodi, {F. Stephen} and Euan Walpole and Adil Daud and Arance, {Ana S.} and Ewan Brown and Christoph Hoeller and Laurent Mortier and Jacob Schachter and Jianmin Long and Scot Ebbinghaus and Nageatte Ibrahim and Marcus Butler",

note = "Publisher Copyright: {\textcopyright} 2018, Cancer Research UK.",

year = "2018",

month = sep,

day = "11",

doi = "10.1038/s41416-018-0207-6",

language = "אנגלית",

volume = "119",

pages = "670--674",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "6",

}

Hamid, O, Robert, C, Ribas, A, Hodi, FS, Walpole, E, Daud, A, Arance, AS, Brown, E, Hoeller, C, Mortier, L, Schachter, J, Long, J, Ebbinghaus, S, Ibrahim, N & Butler, M 2018, 'Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006', British Journal of Cancer, vol. 119, no. 6, pp. 670-674. https://doi.org/10.1038/s41416-018-0207-6

TY - JOUR

T1 - Antitumour activity of pembrolizumab in advanced mucosal melanoma

T2 - a post-hoc analysis of KEYNOTE-001, 002, 006

AU - Hamid, Omid

AU - Robert, Caroline

AU - Ribas, Antoni

AU - Hodi, F. Stephen

AU - Walpole, Euan

AU - Daud, Adil

AU - Arance, Ana S.

AU - Brown, Ewan

AU - Hoeller, Christoph

AU - Mortier, Laurent

AU - Schachter, Jacob

AU - Long, Jianmin

AU - Ebbinghaus, Scot

AU - Ibrahim, Nageatte

AU - Butler, Marcus

PY - 2018/9/11

Y1 - 2018/9/11

N2 - Background: Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT01866319). Methods: Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) or 10 mg/kg Q2W or Q3W. Response was assessed by independent central review per RECIST v1.1. Results: 1567 patients were treated and 84 (5%) had mucosal melanoma. Fifty-one of 84 were ipilimumab-naive. In patients with mucosal melanoma, the objective response rate (ORR) was 19% (95% CI 11–29%), with median duration of response (DOR) of 27.6 months (range 1.1 + to 27.6). Median progression-free survival (PFS) was 2.8 months (95% CI 2.7–2.8), with median overall survival (OS) of 11.3 months (7.7–16.6). ORR was 22% (95% CI 11–35%) and 15% (95% CI 5–32%) in ipilimumab-naive and ipilimumab-treated patients. Conclusion: Pembrolizumab provides durable antitumour activity in patients with advanced mucosal melanoma regardless of prior ipilimumab.

AB - Background: Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT01866319). Methods: Patients received pembrolizumab 2 mg/kg every 3 weeks (Q3W) or 10 mg/kg Q2W or Q3W. Response was assessed by independent central review per RECIST v1.1. Results: 1567 patients were treated and 84 (5%) had mucosal melanoma. Fifty-one of 84 were ipilimumab-naive. In patients with mucosal melanoma, the objective response rate (ORR) was 19% (95% CI 11–29%), with median duration of response (DOR) of 27.6 months (range 1.1 + to 27.6). Median progression-free survival (PFS) was 2.8 months (95% CI 2.7–2.8), with median overall survival (OS) of 11.3 months (7.7–16.6). ORR was 22% (95% CI 11–35%) and 15% (95% CI 5–32%) in ipilimumab-naive and ipilimumab-treated patients. Conclusion: Pembrolizumab provides durable antitumour activity in patients with advanced mucosal melanoma regardless of prior ipilimumab.

UR - http://www.scopus.com/inward/record.url?scp=85053052865&partnerID=8YFLogxK

U2 - 10.1038/s41416-018-0207-6

DO - 10.1038/s41416-018-0207-6

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 30202085

AN - SCOPUS:85053052865

SN - 0007-0920

VL - 119

SP - 670

EP - 674

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 6

ER -

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this